Perhaps you think it's impossible to score another 1,000% gain off this "tech titan" stock. Think again. An unusual strategy lets you virtually "recreate" gains off the biggest companies you thought had come and gone. CLICK HERE to see how it works.
Molson Coors Readies For Beverage Wars
by The Investment U Research Team
Molson Coors Brewing Co (NYSE: TAP) announced impressive numbers this morning, on earning that doubled in the first quarter. It sent the stock up over 10%. They credit this achievement to an aggressive cost cutting strategy.
Interesting that its biggest competitor, the Anheuser-Busch InBev (EBR: ABI) conglomerate, is also aggressively cutting costs from the bloated Anheuser-Busch Company.
You’ll see – or, more correctly won’t see – fewer Superbowl ads, fewer television slots, and a much smaller presence in sports programs and endorsements from both of these companies. Frugality is back in vogue.
Molson Coors and InBev have been cutting bonuses, reducing expenses and removing fat with the zeal of a liposuction clinic. And ultimately this cost cutting will mean sizable profits for investors.
It’s a new stage in the ongoing beverage wars that we’ve seen in both alcoholic and non-alcoholic beverages.
The question is whether these brewing behemoths will become as antagonistic as the PepsiCo (NYSE: PEP) – Coca-Cola (Nasdaq: COKE) relationship. That fight forced both companies to put their best foot forward and created lean profit machines. We can only hope the same goes for Molson Coors and Anheuser-Busch InBev.
Symbols mentioned in this article: TAP, ABI, PEP and COKE.
- Pepsico and AmBev – a Cola and a Beer, Together?
- Send Your Portfolio To Happy Hour With These Beer-Loving Stocks
- Coke Wins NCAA Brackets
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
Investment U RSS Feed